Today: 9 June 2026

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Capital One stock drops on Trump’s 10% credit-card rate cap talk as $425 million depositor settlement advances

Capital One stock drops on Trump’s 10% credit-card rate cap talk as $425 million depositor settlement advances

Capital One shares fell 6.4% to $233.20 in after-hours trading Monday after Donald Trump proposed capping credit-card interest rates at 10% for one year starting Jan. 20. A federal judge gave preliminary approval to Capital One’s revised $425 million settlement with depositors over savings-account rates. Investors await more details and the company’s Jan. 22 earnings call.
12 January 2026
······
Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short

Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short

Alnylam shares fell 6.7% to $370.91 in after-hours trading Monday after the company issued 2026 sales guidance and launched its “Alnylam 2030” plan. Preliminary Q4 sales of Amvuttra reached about $827 million, missing some estimates. Management projected 2026 net product revenue of $4.9–$5.3 billion, mostly from its TTR franchise. The company targets over 25% annual revenue growth through 2030.
12 January 2026
···
iRhythm (IRTC) stock drops after JPM update points to $880 million 2026 revenue

iRhythm (IRTC) stock drops after JPM update points to $880 million 2026 revenue

iRhythm shares fell 5.6% to $169.30 in late trading Monday after the company forecast 2026 revenue of $870–$880 million and an adjusted EBITDA margin of 11.5%–12.5%. Investors focused on the lack of detailed cost and margin data, as well as an upcoming corporate name change. About 1.35 million shares traded, with the stock swinging between $157.34 and $179.82. The company’s update remains preliminary.
12 January 2026
··
Urban Outfitters stock slides despite “record” holiday sales — what spooked URBN shares

Urban Outfitters stock slides despite “record” holiday sales — what spooked URBN shares

Urban Outfitters shares fell 12% after hours Monday despite a 9% rise in holiday sales, as investors worried about profit margins and future demand. The stock touched $70.27 before recovering to $71.49. Apparel stocks broadly declined after weak forecasts from Abercrombie & Fitch and Birkenstock. Urban Outfitters opened 58 new stores and closed seven in the past eleven months.
12 January 2026
··
Dave Inc stock drops nearly 9% as fintech lenders slide; CPI test looms for DAVE

Dave Inc stock drops nearly 9% as fintech lenders slide; CPI test looms for DAVE

Dave Inc (DAVE.O) shares fell 8.8% to $218.29 Monday after President Trump called for a 10% cap on credit card interest rates, sparking a selloff in credit-sensitive stocks. About 1.1 million Dave shares traded by mid-afternoon. The drop mirrored declines in other fintechs, including Upstart and Affirm. Dave also faces a Justice Department complaint alleging it misled users about fees, which the company disputes.
12 January 2026
··
Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Arcutis Biotherapeutics shares fell 8.7% to $25.76 Monday after the company set a 2026 net product sales target of $455–$470 million for its ZORYVE franchise. The company reported $99.2 million in net product revenue last quarter and ended September with $191.4 million in cash. Arcutis plans to expand its sales team by 20% and expects key clinical trial data in early 2026. The stock hit a session low of $25.51.
12 January 2026
··
Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal

Caris Life Sciences (CAI) stock drops on preliminary 2025 results, Everlywell cancer-screening deal

Caris Life Sciences shares fell 8.5% to $26.08 in afternoon trading after the company reported preliminary 2025 revenue near $800 million, up 94%, but warned of significant prior-period adjustments. The company also announced a partnership with Everlywell to develop a blood-based early cancer detection test, with more details expected at the JPMorgan Healthcare Conference later Monday.
12 January 2026
··
HealthEquity stock slides nearly 10% after 2027 outlook; JPM conference is next test

HealthEquity stock slides nearly 10% after 2027 outlook; JPM conference is next test

HealthEquity shares fell about 10% Monday after the company issued a cautious initial fiscal 2027 outlook, projecting revenue between $1.38 billion and $1.41 billion and an HSA cash yield near 3.75%. The stock last traded at $84.62, down $9.53. Executives will present at the J.P. Morgan Healthcare Conference on Tuesday. The company reaffirmed its 2026 guidance.
12 January 2026
··
Synchrony Financial stock slides on Trump’s 10% credit-card rate cap pitch — what investors watch next

Synchrony Financial stock slides on Trump’s 10% credit-card rate cap pitch — what investors watch next

Synchrony shares fell 8.2% to $79.76 after Donald Trump called for a one-year 10% cap on credit card interest rates, sparking fears of tighter regulation and profit declines. Analysts said such a cap would require congressional approval. Bread Financial, Capital One, and Barclays also saw declines. Separately, Synchrony expanded CareCredit integration with Fiserv’s Clover platform, now reaching over 40,000 providers.
12 January 2026
·
Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

Summit Therapeutics shares fell 11% to $17.46 Monday after announcing a U.S. FDA biologics license application for its lung cancer drug ivonescimab. The company also disclosed a clinical trial collaboration with GSK to test a combination regimen in solid tumors. Investors are watching for the FDA’s next procedural step and updates from the J.P. Morgan Healthcare Conference.
12 January 2026
·
Figure Technology Solutions stock drops nearly 10% after FIGR posts preliminary Q4 loan data

Figure Technology Solutions stock drops nearly 10% after FIGR posts preliminary Q4 loan data

Figure Technology Solutions shares fell 9.6% to $52.50 Monday after releasing preliminary Q4 metrics. The company reported $2.705 billion in Q4 consumer loan marketplace volume, up 131% from a year earlier, and $328 million in $YLDS stablecoin circulation. Investors are watching for Tuesday’s U.S. CPI report and the Fed’s January meeting for rate signals.
12 January 2026
··
Bread Financial (BFH) stock slides on Trump’s 10% credit-card rate cap push; what’s next

Bread Financial (BFH) stock slides on Trump’s 10% credit-card rate cap push; what’s next

Bread Financial shares fell 10.8% to $71.65 Monday after Donald Trump proposed a one-year 10% cap on credit card interest rates, with no details on enforcement. The selloff spread to other lenders, including Synchrony and Capital One. Analysts questioned the proposal’s viability, citing legal hurdles. Bread Financial reports earnings Jan. 29, with investors watching for commentary on policy risks.
12 January 2026
·····
GeneDx (WGS) stock dives on 2026 guidance despite strong 2025 prelims — what to watch next

GeneDx (WGS) stock dives on 2026 guidance despite strong 2025 prelims — what to watch next

GeneDx shares fell about 14% to $115.75 Monday after releasing preliminary 2025 results and 2026 revenue guidance above analyst estimates. The company projected 2026 revenue of $540–$555 million and positive adjusted net income. Investors are awaiting CEO remarks at the Jan. 14 J.P. Morgan Healthcare Conference and the Feb. 23 earnings report for further details. The latest figures remain unaudited and subject to revision.
12 January 2026
·
Lemonade stock hits fresh 52-week high as LMND rallies; traders watch short interest and earnings

Lemonade stock hits fresh 52-week high as LMND rallies; traders watch short interest and earnings

Lemonade shares jumped 7.7% to $85.81 Monday, hitting a new 52-week high amid heavy short interest and volatile trading. About 20% of the float was shorted as of mid-December, raising the risk of sharp moves. Chief insurance officer John Peters sold 10,000 shares Jan. 6 at $80 under a pre-set plan. The next earnings report is expected Feb. 24.
12 January 2026
··
Sarepta stock sinks as Elevidys sales miss, flu delays spill into 2026

Sarepta stock sinks as Elevidys sales miss, flu delays spill into 2026

Sarepta Therapeutics shares fell 13% to $20.73 Monday after a preliminary update showed weaker-than-expected fourth-quarter sales for its Duchenne gene therapy, Elevidys. The company reported $110.4 million in Elevidys revenue for the quarter, below Wall Street’s $122 million estimate. Sarepta cited a severe flu season and delayed six patient infusions to 2026. Final results are due in late February.
12 January 2026
·
Abercrombie & Fitch stock slides 17% after outlook trim puts tariffs back on the tape

Abercrombie & Fitch stock slides 17% after outlook trim puts tariffs back on the tape

Abercrombie & Fitch shares fell 17.3% to $103.26 after the company cut its full-year sales growth forecast and lowered its holiday-quarter outlook. The retailer now expects fiscal 2025 net sales growth of at least 6%, down from a prior 6%–7% range, and factored in $90 million in tariff expenses. Investors are watching the ICR Conference this week for further updates on demand and pricing.
12 January 2026
·
Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens

Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens

Nuvation Bio shares fell 17.7% to $6.62 Monday after announcing a licensing deal with Eisai and releasing initial sales data for its lung-cancer drug. Eisai will pay €50 million upfront for rights outside the U.S., China, and Japan, with further milestone payments possible. Fourth-quarter Ibtrozi sales met estimates, but investors appeared cautious on future prescription growth.
12 January 2026
····
1 … 250 251 252 253 254 … 588

Stock Market Today

  • SpaceX IPO 2026: Key Facts and Considerations
    June 8, 2026, 6:15 PM EDT. SpaceX, Elon Musk's private aerospace giant, is eyeing an initial public offering (IPO) in 2026. An IPO is when a company offers its shares to the public for the first time. Investors anticipating the SpaceX IPO should note the company's role in satellite technology and space exploration, sectors poised for growth. Market watchers will monitor valuation, timing, and regulatory factors as SpaceX transitions from private funding to public markets. Understanding these elements is crucial for stakeholders considering exposure to aerospace innovation and potential returns.

Latest articles

Volatility Gauge Jumps While Chip Stocks Swing

Volatility Gauge Jumps While Chip Stocks Swing

9 June 2026
The VIX plunged 12% to 18.92 as chip stocks rebounded sharply, with the Philadelphia Semiconductor Index jumping 5.6% and Intel soaring 11.2% after a major Google order, clawing back part of Friday’s $1.3 trillion rout; investors remain cautious ahead of key inflation data, interest rate decisions, and Middle East risks.
UBS Puts $850 Target on Cummins as AI Data Center Wave Fuels Shares

UBS Puts $850 Target on Cummins as AI Data Center Wave Fuels Shares

9 June 2026
UBS upgraded Cummins to Buy and hiked its price target to $850 from $565, citing surging data-center backup power demand and a stronger North American truck cycle; Cummins shares jumped 3.3% to $672.68 as UBS projected 2028 EPS of $41.25, topping consensus, and flagged double-digit Power business growth and raised long-term targets as key drivers.
UiPath Stock Slips Near $11 as Wall Street Questions the AI Automation Bounce

UiPath Stock Slips Near $11 as Wall Street Questions the AI Automation Bounce

8 June 2026
UiPath shares dipped 0.7% to $11.17 despite a strong quarter and raised outlook, as investors focused on slow annual recurring revenue growth and analyst caution, with Morgan Stanley cutting its price target and BofA maintaining Underperform, citing the need for clearer evidence that AI-driven automation can accelerate durable contract revenue.
IREN Shares Rally After Bitcoin Rebound and $4.4 Billion AI Data Center Move

IREN Shares Rally After Bitcoin Rebound and $4.4 Billion AI Data Center Move

8 June 2026
IREN surged 9% to $59.19 as investors returned to crypto and AI infrastructure stocks after last week’s selloff, driven by a $3.65 billion investment-grade GPU financing to support its Microsoft AI cloud contract and news of a planned 800MW data-center in Australia, but future gains hinge on execution, contract delivery, and bitcoin price stability.
SmartKem Shares Jump 100% on SRx Investment, SMTK in Focus

SmartKem Shares Jump 100% on SRx Investment, SMTK in Focus

8 June 2026
SmartKem shares soared as much as 150% to $1.135 before settling at $0.84 after SRx Health Solutions disclosed a 4.99% stake and purchase of convertible preferred securities, injecting new investor interest as SmartKem faces a Sept. 1 Nasdaq delisting risk for trading below $1 and warns of “substantial doubt” about its ability to continue as a going concern.
Go toTop